Clinical Trial Update: Novel PET Radioligand as an Inflammatory Biomarker in Musculoskeletal Conditions [Phase 1]

View source ↗

Summary

Phase 1 trial of a novel PET radioligand as an inflammatory biomarker for musculoskeletal conditions; the study was terminated and results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myositis
• Rheumatoid Arthritis

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: Myositis, Inflammatory | Phase 1 | Status: TERMINATED | Results posted: 2025-09-16